Monoacylglycerol lipase contributes to pathogenesis of Alzheimer's disease
Name
nihms414341.pdf
Size
3.31 MB
Format
Adobe PDF
Checksum (MD5)
f4672d9a3b7a68b006aa5a6f23e6cbe3
Author(s)
Chen, Rongqing
Zhang, Jian
Wu, Yan
Wang, Dongqing
Feng, Guoping
Tang, Ya-Ping
Chen, Chu
Date Issued
July 2012
Journal
Alzheimer's & Dementia
Publisher
Elsevier
Citation
Chen, Rongqing, et al. “Monoacylglycerol Lipase Contributes to Pathogenesis of Alzheimer’s Disease.” Alzheimer’s & Dementia 8, 4 (July 2012): P703 © 2012 Elsevier
Version
Author's final manuscript
Abstract
Alzheimer’s disease (AD) is the most common cause of dementia among older people. There are no effective medications currently available to prevent and treat AD and halt disease progression. Monoacylglycerol lipase (MAGL) is the primary enzyme metabolizing the endocannabinoid 2-arachidonoylglycerol in the brain. We show here that inactivation of MAGL robustly suppressed production and accumulation of β-amyloid (Aβ) associated with reduced expression of β-site amyloid precursor protein cleaving enzyme 1 (BACE1) in a mouse model of AD. MAGL inhibition also prevented neuroinflammation, decreased neurodegeneration, maintained integrity of hippocampal synaptic structure and function, and improved long-term synaptic plasticity, spatial learning and memory in AD animals. While the molecular mechanisms underlying MAGL inhibition-produced beneficial effects remain to be determined, our results suggest that MAGL,which regulates endocannabinoid and prostaglandin signaling, contributes to pathogenesis and neuropathology of AD and thus is a promising therapeutic target for the prevention and treatment of AD.
MIT Department
Massachusetts Institute of Technology. Department of Brain and Cognitive Sciences
McGovern Institute for Brain Research at MIT
Terms of Use
Creative Commons Attribution-NonCommercial-NoDerivs License
Persistent DSpace Link
DOI of Published Version
https://doi.org/10.1016/j.jalz.2012.05.1894
